194 related articles for article (PubMed ID: 38630538)
1. Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens.
Radu P; Kumar G; Cole A; Fameli A; Guthrie M; Annemans L; Geissler J; Italiano A; O'Rourke B; Xoxi E; Steuten L
Oncologist; 2024 Jun; 29(6):465-472. PubMed ID: 38630538
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany.
Schiller J; Eckhardt H; Schmitter S; Alber VA; Rombey T
Value Health; 2023 Jun; 26(6):854-864. PubMed ID: 36709043
[TBL] [Abstract][Full Text] [Related]
4. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
5. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
6. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
7. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies.
Russo A; Incorvaia L; Malapelle U; Del Re M; Capoluongo E; Vincenzi B; Chiari R; Cortesi L; Danesi R; Florena AM; Fontanini G; Gori S; Marchetti A; Normanno N; Pinto C; Sangiolo D; Silvestris N; Tagliaferri P; Tallini G; Cinieri S; Beretta GD
Crit Rev Oncol Hematol; 2021 Sep; 165():103436. PubMed ID: 34371157
[TBL] [Abstract][Full Text] [Related]
8. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
9. Integrating genomics into clinical oncology: ethical and social challenges from proponents of personalized medicine.
McGowan ML; Settersten RA; Juengst ET; Fishman JR
Urol Oncol; 2014 Feb; 32(2):187-92. PubMed ID: 24445286
[TBL] [Abstract][Full Text] [Related]
10. Consensus Statements on Precision Oncology in the China Greater Bay Area.
Lam TC; Cho WC; Au JS; Ma ES; Lam ST; Loong HH; Wong JWH; Wong SNM; Lee VH; Leung RC; Lau JK; Kam MT; Mok FS; Lim FM; Nyaw JS; Tin WW; Cheung KM; Chan OS; Kwong PW; Cheung FY; Poon DMC; Chik JY; Lam MH; Chan LW; Wong SC; Cao YB; Hui CV; Chen JZ; Chang JH; Kong SF; El Helali A;
JCO Precis Oncol; 2023 Jun; 7():e2200649. PubMed ID: 37315266
[TBL] [Abstract][Full Text] [Related]
11. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
12. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
13. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
Schmidt KT; Chau CH; Price DK; Figg WD
J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
[TBL] [Abstract][Full Text] [Related]
14. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
15. Evolution of precision oncology-guided treatment paradigms.
DasGupta R; Yap A; Yaqing EY; Chia S
WIREs Mech Dis; 2023 Jan; 15(1):e1585. PubMed ID: 36168283
[TBL] [Abstract][Full Text] [Related]
16. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
Arnall JR; Petro R; Patel JN; Kennedy L
J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
[TBL] [Abstract][Full Text] [Related]
17. An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.
Le Tourneau C; Perret C; Hackshaw A; Blay JY; Nabholz C; Geissler J; Do T; von Meyenn M; Dienstmann R
JCO Precis Oncol; 2022 Jul; 6():e2200019. PubMed ID: 35939770
[TBL] [Abstract][Full Text] [Related]
18. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions.
Weymann D; Pollard S; Lam H; Krebs E; Regier DA
Value Health; 2023 Nov; 26(11):1608-1617. PubMed ID: 37543205
[TBL] [Abstract][Full Text] [Related]
19. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
20. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A
Eur J Cancer; 2023 Nov; 194():113278. PubMed ID: 37820553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
